The TBI Action Alliance

About the Brain Trauma Blueprint

Brain Trauma Blueprint ProcessThe Brain Trauma Blueprint is a roadmap to advance precision diagnostics and therapeutics for survivors of brain trauma by outlining research endeavors and fostering collaboration across the broader stakeholder community.

One pivotal component of the Blueprint Process is to convene key stakeholders at a State of the Science Summit, which aims to survey the current scientific knowledge, identify knowledge gaps and consider new scientific and clinical models and actionable research priorities that will inform funding efforts and accelerate the development of a new generation of precision diagnostics and targeted therapeutics. By fostering collaboration across the broader stakeholder community, we will enable translational research gaps to be bridged and achieve solutions sooner for those suffering from trauma-related brain disorders.

The need is significant.

  • Most people will experience at least one traumatic event in their lifetime.
  • Estimates suggest approximately 24.4 million Americans suffer from PTSD.
  • An average of 2.8 million Americans will experience a traumatic brain injury every year.
  • Recent research suggests that even a single concussive event may cause neurocognitive changes in individuals at any point post-injury.
  • The morbidity and mortality of PTSD and chronic neuropsychiatric effects of TBI are further magnified by the substantial disruptions in family, workplace, and societal contexts, all contributing to the enormous clinical, social, and financial burden of ineffectively treated trauma-related brain disorders.

The resolutions are few.

  • There is a paucity of therapeutic options for these conditions.
  • The developmental pipeline is meager compared with other prevalent CNS disorders.
  • There are no objective diagnostics for PTSD or for the chronic neuropsychiatric effects of TBI.
  • These disorders also lack validated treatment response and prognostic biomarkers and objective outcome measures.
  • This situation is related to, and exacerbated by, the limited understanding of the biological underpinnings of these disorders.

Together, we will empower all stakeholders to be informed and strategic architects through the Brain Trauma Blueprint.

Recent News

Cohen Veterans Bioscience Announces ‘Call for National TBI Action Coalition’

A new Community Coordination model to accelerate a first generation of diagnostics and treatments for Traumatic Brain Injury (TBI)

Cohen Veterans Bioscience (CVB), a brain research and advocacy non-profit organization is pleased to announce it is launching a Call for a TBI Action Coalition on the eve of Veterans Day.

This ‘Call for Coalition’ is an actionable outcome from the recent Cohen Veterans Bioscience led Brain Trauma Blueprint Action Summit held October 18-19, 2022, at the Ronald Reagan Building and International Trade Center in Washington DC.  CVB convened national stakeholder groups across government, academia, foundations, industry, and individuals with lived experience to develop the plan to execute the TBI Precision Research Roadmap – a consensus driven plan that outlines the research projects & policies needed to accelerate a first generation of precision diagnostics and targeted treatments for brain trauma and also the systemic changes required to ensure that all those suffering from trauma-related brain disorders can get access to these new innovations, and other support and care, they so desperately need.

Continue Reading

Quote from Dr. Magali Haas

Recent Publications

Understanding TBI Biomarkers to Advance Personalized Treatments

Traumatic Brain Injury: A Framework to Advance Biomarker Development for Diagnosis, Outcome Prediction, and Treatment

Published in the Journal of Neurotrauma, the article focuses on the pressing need for multi-modal biomarkers for traumatic brain injury to guide the development of diagnostics and personalized, targeted therapies.

Biomarkers enable researchers and clinicians to identify cellular injury, monitor clinical improvement (or deterioration), and make the most precise, effective treatment decisions. By understanding how TBI biomarkers change over time and as a measure of different mechanisms of TBI, clinicians and researchers can identify appropriate time windows and target populations for intervention as the injury evolves.

Learn more about this publication

Quote from Dr. Magali Haas